Lorediplon

Last updated
Lorediplon
Lorediplon.svg
Clinical data
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers
  • N-{2-fluoro-5-[3-(thiophen-2-ylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl}-N-methylacetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C20H15FN4O2S
Molar mass 394.42 g·mol−1
3D model (JSmol)
  • O=C(c2cnn3c(c1ccc(F)c(N(C(=O)C)C)c1)ccnc23)c4sccc4
  • InChI=1S/C20H15FN4O2S/c1-12(26)24(2)17-10-13(5-6-15(17)21)16-7-8-22-20-14(11-23-25(16)20)19(27)18-4-3-9-28-18/h3-11H,1-2H3 Yes check.svgY
  • Key:NQPOCLFSADOXBR-UHFFFAOYSA-N Yes check.svgY
   (verify)

Lorediplon (INN) is a nonbenzodiazepine of the pyrazolopyrimidine family that is being pursued as a treatment for insomnia but has not completed development. [1] [2]

See also

Related Research Articles

An international nonproprietary name (INN) is an official generic and nonproprietary name given to a pharmaceutical drug or an active ingredient. INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. The INN system has been coordinated by the World Health Organization (WHO) since 1953.

<span class="mw-page-title-main">Fenpiverinium</span>

Fenpiverinium is an anticholinergic and antispasmodic compound; it is marketed as a combination drug with pitofenone hydrochloride and either nimesulide or metamizole in Eastern Europe and India to treat smooth muscle spasms and pain.

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.

Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator.

Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.

Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis. It binds to IL17A and acts as an immunomodulator.

<span class="mw-page-title-main">Pacritinib</span> Medication used to treat myelofibrosis

Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).

Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC

Lifastuzumab vedotin is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.

Ulocuplumab is a monoclonal antibody designed for the treatment of hematologic malignancies.

Seribantumab is a monoclonal antibody designed for the treatment of cancer.

Depatuxizumab mafodotin is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.

References

  1. ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2): 179.
  2. ↑ Misra AK, Sharma PK (2020). "Sedative and Hypnotic Drugs". In Uddin MS, Rashid M (eds.). Advances in Neuropharmacology: Drugs and Therapeutics. New York: Apple Academic Press. p. 441. ISBN   978-0-429-51589-7.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.